Response with omalizumab varies by asthma type


eMediNexus    13 October 2017

A multicenter, retrospective study, presented at the European Academy of Allergy and Clinical Immunology Congress 2017, suggests that the benefit of omalizumab is greater in patients who have early-onset allergic asthma or severe asthma with frequent exacerbations as compared to those who have other asthma phenotypes.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.